Introduction
Bladder cancer is the fourth most common noncutaneous malignancy and the eighth leading cause of cancer death among men in the United States, with an estimated 13, 750 deaths annually (1) . Approximately 30% to 40% of patients with high-risk non-muscleinvasive bladder cancer will have progression to more advanced disease within 5 years, and up to 34% of these patients will ultimately die of bladder cancer (2, 3) . Radical cystectomy, which is the mainstay of treatment for muscle-invasive bladder cancer, has a failure rate of 30% to 45%, largely because of recurrences in the form of distant metastases (4) . Overall, only 20% to 40% of patients with advanced bladder cancer survive 5 years, despite aggressive multimodal therapy (5, 6) . To improve survival rates, there is an urgent need not only to improve current chemotherapeutic regimens but also to develop novel chemotherapeutic strategies to prevent or delay disease progression.
In recent years, mammalian target of rapamycin (mTOR), a key downstream protein kinase of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway, has been recognized to play a central role in controlling cancer cell growth (7) . AKT and mTOR function as "master switch" proteins in cancer cells to modulate metabolism, the cell cycle, and apoptosis (8) . Inhibition of mTOR results in a wide variety of effects on normal and malignant cells, including induction of apoptosis and inhibition of cell cycle progression, cell growth, angiogenesis, endothelial cell proliferation, and protein translation (7, 9) . mTOR inhibitors such as RAD001 (everolimus; Novartis) and AP23573 (Ariad Pharmaceuticals) have been shown to exhibit potent preclinical activities against a wide variety of cancers, including rhabdosarcoma, neuroblastoma, glioblastoma, small cell lung cancer, renal cancer, osteosarcoma, pancreatic cancer, leukemias, B-cell lymphoma, and breast and colon cancer (9) . RAD001 has been clinically approved for the treatment of renal cancer.
Given the breadth of its downstream effects on cancer cells, the PI3K/AKT/mTOR signaling pathway may represent a promising molecular target for bladder cancer. In support of this hypothesis, Wu et al recently showed that 55% of human bladder tumors analyzed had increased expression of phosphorylated AKT (pAKT) and that inhibition of the PI3K pathway could drastically reduce the invasive capacity of bladder cancer cell lines (10) . PTEN mutations are also reported to be present in up to 23% of patients with bladder transitional cell carcinoma (10) . In addition, we reported that inhibition of the AKT pathway by forced expression of PTEN reduced the growth of bladder cancer cells, and that the PTEN/AKT pathway could be an important therapeutic target for bladder cancer (11) . AKT, a serine-threonine kinase that is dependent on PI3K signaling for activation, is known to be involved in cell proliferation and a variety of anti-apoptotic pathways (12) . Inactivation of the tumor suppressor gene PTEN, which is mapped to chromosome 10q23, has also been suggested to be involved in bladder cancer progression (13) (14) (15) (16) . Recently, a synergistic relationship between deletion of p53 and PTEN, which deregulates of mTOR signaling was shown to promote tumorigenesis in a murine model of bladder cancer (17), and rapamycin has been shown to inhibit the proliferation of bladder cancer cells in vitro (18 study had shown that mTOR inhibition by RAD001 has anti-proliferative activity in bladder cancer, supporting this hypothesis (19) .
Here, we report the effects of RAD001 on bladder cancer cell growth both in vitro in several bladder cancer cell lines with different genetic backgrounds and in vivo in a nude mouse xenograft model.
Materials and Methods
Cell culture. The transitional cell carcinoma cell lines UM-UC-3, UM-UC-6, UM-UC-9, and UM-UC-14 (Table 1 ) were obtained at source (H. Barton Grossman, MD) from cryopreserved cells frozen over a span of more than 25 years. UM-UC-3 was also obtained from the American Type Culture Collection (ATCC; Manassas, VA). The cell lines were authenticated within 6 months of performing the experiments (20) . These cell lines were maintained in Eagle's minimum essential medium (Mediatech Inc.) supplemented with 2 mM L-glutamine, 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (20) . All cultures were free of bacterial, fungal, and mycoplasmal contamination.
Reagents and drug preparation. RAD001 and placebo were obtained from Novartis Pharma AG. For in vitro experiments, RAD001 was prepared in DMSO. For animal studies, RAD001 was prepared at 2% (w/w) (20 mg/g) in a microemulsion vehicle, which
Research. was diluted in 5% glucose in double-distilled water just before administration by oral gavage.
In vitro cell growth. Cell growth was measured using a crystal violet assay as previously described (21) . Bladder cancer cells were plated into six-well plates at a density of chamber with 5% CO 2, for 2 h. The radiolabeled protein-uptake assay was performed as previously described (22) . The radioactivity of the solution was measured as disintegrations per minute (DPM) using a liquid scintillation counter (Beckman LS 6500, Global Medical Instrumentation, Inc.). All experiments were performed in triplicate and repeated once.
Western blot analysis. Cells were harvested at 70% to 80% confluence and cell lysates were obtained as previously described (11 Fig. 1 ). The tissue specimens were evaluated by light microscopy, and the immunostaining was scored by two independent observers who were blinded to which samples (i.e., drug-treated or placebo) they were evaluating. Only cytoplasmic staining was considered for scoring. The staining intensity was assigned a score for the most dominantly stained area and this stained area should occupy at least 20% of the specimen.
The intensity of staining was scored on a scale of 0 to 3+, with 0 for no staining, 1+ for weak staining intensity, 2+ for moderate staining intensity, and 3+ for the most intense staining (Examples of staining intensities are shown in supplementary Fig. 2 ) . The microvessel density was measured by microscopy at 100X magnification by counting the number of blood vessels (stained with anti-CD31) in each of five fields per tumor sample to obtain an average measurement (25) . The fields with the highest density of blood vessels on the slide were selected for analysis. The CD31 expression data were analyzed with repeated measures analysis of variance. Statistical significance was determined to be P < 0.05.
Results

Growth-inhibitory effects of RAD001 in vitro.
The bladder cancer cell lines UM-UC-3, UM-UC-6, UM-UC-9, and UM-UC-14 were treated with increasing doses of RAD001 (0.1 nM to 100 nM) and incubated for up to 6 days. RAD001 inhibited the growth of all bladder cancer cells tested in a dose-dependent manner, with a partial loss of response seen 4 days after initial treatment (Fig. 1A) . The UM-UC-14 cell line was the most sensitive to RAD001, with an IC 50 of 0.1 nM, the UM-UC-3 and UM-UC-6 cell lines had moderate sensitivities, with IC 50s of 0.5 nM, and the UM-UC-9 cell line was the least sensitive, with an IC 50 of 10 nM. Retreatment of cells with RAD001 (at a dose corresponding to each cell line's IC 50 ) 3 days after the initial therapy augmented the growth inhibition in all four bladder cancer cell lines (Fig. 1B) . The timing of redosing at day 3 was based on the observation that there was loss of response to RAD001 in all four cell lines from day 4 of incubation ( (Fig. 1C) . This was consistent with the growth inhibitory effects of RAD001 on bladder cancer cells seen in the crystal violet assays (Fig. 1A) .
Cell cycle and apoptosis. All four cell lines were treated once with increasing doses of RAD001 (0.1 nM, 0.5 nM, 10 nM, and 100 nM), and cell cycle analysis was performed at various time points (24, 48 , and 72 h). We saw no specific growth phase arrest with a single treatment of RAD001 in any of the four cell lines tested (Fig 2A) . When we retreated UM-UC-6 and UM-UC-9 cell lines with RAD001, 3 days after the initial dose, only the UM-UC-6 cells were arrested in the G0/G1 phase (Fig 2A) . We did not see any evidence of apoptosis in any of the four cell lines tested by Annexin V assays, which
were performed 12 and 24 h after a single treatment of cells with RAD001, even at doses
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on July 15, 2017. © 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from as high as 100 nM (data not shown). We corroborated these findings with PI exclusion assays 24 and 48 h after RAD001 treatment, which showed that RAD001 induced nonapoptotic cell death at the IC 50 doses in all of the bladder cancer cell lines except UM-UC-9 (Fig. 2B , data not shown for cell lines UM-UC-3 and UM-UC-14).
Protein synthesis. Using a radioactively labeled amino acid (leucine), we demonstrated that RAD001 inhibited protein synthesis in all four bladder cancer cell lines ( Supplementary Fig. 3 , data not shown for cell lines UM-UC-3 and UM-UC-14).
Downstream effects of mTOR blockade by RAD001.
To investigate the effects of RAD001 treatment on mTOR signaling, we used western blotting to analyze the levels of the phosphorylated forms of mTOR, p70S6K, 4E-BP-1 and non-phosphorylated forms of mTOR and p70S6K, after a single 24-h exposure of UM-UC-3, UM-UC-6, UM-UC-9, and UM-UC-14 cells to various doses of RAD001. In all four cell lines, the levels of the phosphorylated forms of mTOR, p70S6K, and 4E-BP-1 were reduced with increasing doses of RAD001, but the effects of RAD001 on the non-phosphorylated form of mTOR protein levels in each cell line were different, with only UM-UC-3 and UM-UC-6 having a slight decrease in mTOR levels with increasing RAD001 dose (Fig. 3) . No downsteam effect of RAD001 was seen in the non-phosphorylated form of p70S6K in all 4 cell lines (Fig 3) . Overall, the effects of RAD001 on the levels of these proteins in the mTOR signaling pathway did not correlate with the relative sensitivity of each cell line to the growth inhibitory effects of RAD001.
Research. Effects of RAD001 in vivo. UM-UC-3, UM-UC-6, and UM-UC-9 cells were implanted subcutaneously into nude mice, and when the xenograft tumors reached 5 mm in diameter, the mice were treated with RAD001 by oral gavage twice per week for 1 month. RAD001 significantly inhibited the growth of tumors derived from all three cell lines (Fig. 4) . Immunohistochemical analysis of tumor tissue samples demonstrated reduced expression of phosphorylated p70S6K in the RAD001-treated UM-UC-3-and UM-UC-6-derived tumors compared with control-treated tumors, while the expression of phosphorylated p70S6K in RAD001-treated UM-UC-9-derived tumors was unchanged (Table 2 and Fig. 5 ). There was no difference in the expression level of phosphorylated mTOR between the RAD001-treated and control-treated tumors. For the UM-UC-3-and UM-UC-9-derived tumors, phosphorylated AKT expression was reduced in the RAD001-treated compared with control-treated tumors, but the phosphorylated AKT levels were unchanged between the RAD001-treated and control-treated UM-UC-6-derived tumors.
The vascular density in the tumors was measured by counting the number of blood vessels that expressed CD31. RAD001 treatment did not affect the vascular density of UM-UC-6-derived tumors (P = 0.5503; Table 2 and Fig. 5 ). However, RAD001 treatment modestly reduced the vascular density of the UM-UC-3-derived tumors (P = 0.0597) and significantly reduced the vascular density of the UM-UC-9-derived tumors (P = 0.036; Table 2 and Fig. 5 ). Expression levels of VEGF were similar in the RAD001-and control-treated tumors derived from all three cell lines ( Table 2 ), suggesting that the changes in vascular density were not due to changes in the VEGF pathway. 
Discussion
In this study we show that the inhibition of the mTOR pathway effectively reduces the growth of bladder cancer cells, in spite of the variations in genetic backgrounds of the bladder cancer cell lines. This presents further evidence that the PI3K/AKT/mTOR signaling pathway is important in bladder cancer and that mTOR may be used as a molecular target for bladder cancer therapy. (Table 1) (11, 27) . The effect of mTOR inhibition on AKT activity has been reported to be variable; depending on the cell type, and inhibition of mTOR has led to increased activation, no change, or reduced phosphorylation of AKT after prolonged treatment (28, 29) . We show that RAD001 reduces the expression of AKT in the UM-UC-3-and UM-UC-9-derived tumors, both cell lines constitutionally express phosphorylated AKT (Tables 1A and 1B ). This reduction in AKT expression was not seen in the RAD001-treated UM-UC-6-derived tumors, a cell line that has a normal PTEN/AKT pathway (Tables 1 and 2 we did not find this relationship to be present in our panel of bladder cancer cells, despite having chosen cell lines with known variable PTEN/AKT status for our study (19, 30) . mTOR comprises two multiprotein complexes: mTOR complexes 1 and 2 (mTORC1 and mTORC2) (28) . It is known that mTORC1 is rapamycin-sensitive and its activation results in phosphorylation of 4EBP1 and S6K1, while mTORC2 may be regulated by rapamycin to cause either AKT activation or inactivation (28) . The variable effect of RAD001 on phosphorylated AKT levels in different bladder cancer cell types could be due in part to the differential effects of mTOR inhibition on mTORC1 and mTORC2 in different cell lines. The complexity of the multiple pathways involved may be one of the reasons for not seeing a direct relationship between the PTEN/AKT status and effects of mTOR inhibition.
Our in vitro results demonstrate that RAD001 inhibits the growth of bladder cancer cells at concentrations that are physiologically safe in humans (31) . However, the response of bladder cancer cells to RAD001 in vitro was heterogeneous, with UM-UC-14 being the most sensitive cell line and UM-UC-9 being the least sensitive. The IC 50 of UM-UC-9 was approximately 20 times higher than in the UM-UC-3 and UM-UC-6 cell lines, and 
response of different cell types to single doses of RAD001 was mainly due to the differential effects of mTOR inhibition on downstream effectors. It is known that the downstream effectors of mTOR are 4E-BP1 and S6 kinase 1 (S6K1), both of which are regulators of protein translation (7, 9) . Activation of mTOR leads to phosphorylation of 4E-BP1, which prevents it from binding to eukaryotic initiation factor 4E (eIF4E). EIF4E
is then free to bind to mRNA transcripts and other translation initiation complex proteins and activate cap-dependent translation (7, 28, 32) . S6K1, a key regulator of cell growth, phosphorylates ribosomal protein S6 and enhances the translation of 5'-terminal oligopyrimidine tract mRNAs in some models (28) . S6K1 has also been reported to play a role in glucose homeostasis by phosphorylating insulin receptor substrate 1 and glycogen synthase kinase 3 and by regulating other factors such as eukaryotic initiation factor 4B, programmed cell death 4, eukaryotic elongation factor-2 kinase, and S6K1 Aly/REF-like target (7, 28) . Mansure et al recently suggested that the reduction of phosphorylation levels of S6 activation correlated with the sensitivity of bladder cancer cells to RAD001, and that S6 inhibition may reflect the sensitivity of these cells to mTOR inhibition (19) . In our study, RAD001 reduced the expression of phosphorylated p70S6 kinase and phosphorylated 4E-BP1 in vitro in all cell lines tested. However, we did not observe a correlation between S6 phosphorylation levels and sensitivity to mTOR inhibition by RAD001. One reason for the difference may be due to the fact that the panel of bladder cancer cell lines tested was different in both studies. The differential sensitivity of bladder cancer cells to mTOR inhibition may be due to a variety of other factors, such as variability of mTORC1 and mTORC2 response or activation / inhibition of other pathways in response to mTOR inhibition. It has been shown that mTORC1 and 
S6K may be activated independent of mTOR, possibly through the MEK-ERK signaling pathway (33, 34) . It was also shown that RAD001 can activate MAP Kinse (MAPK), which is mediated by S6K-PI3K-Ras signaling, and that this feedback could be a cause of the poor anticancer activity of mTORC1 inhibitors (35) . These complex relationships between mTOR and other pathways may account for differences in various cell lines'sensitivity to RAD001 and the inability to reliably correlate expression of effectors such as S6K and response to mTOR inhibition. Such relationships deserve further investigation.
Contrary to other reports (7, 19) , we observed that a single treatment of RAD001 did not cause a specific growth phase arrest in any of the cell lines we tested. Retreatment with RAD001 induced G0/G1 arrest in UM-UC-3 and UM-UC-6, but not in UM-UC-9 cells, which are resistant to RAD001 in vitro. Since MAPK is known to regulate transcription of genes that are important for cell cycle, effects of the MAPK feedback loop with mTOR may contribute to the differential effects on cell cycle arrest seen in various cell lines. In our study, we show that RAD001 induced non-apoptotic cell death in all the cell lines tested. As autophagic activation by mTOR inhibition is known to occur, this may be another possible mechanism of bladder cancer cell growth inhibition by RAD001 (24) .
Further evaluation of the relationship between mTOR inhibition and autophagy is currently underway.
Our in vivo data confirm that mTOR inhibition by RAD001 is effective in inhibiting the growth of UM-UC-3, UM-UC-6, and UM-UC-9 bladder cancer cells subcutaneously (Table 1B) .
Interestingly, VEGF expression was not different between the RAD001-and controltreated tumors in any of the three cell lines tested (Table 1B) . On the basis of these findings, we hypothesize that inhibition of protein synthesis through the S6K and 4E-BP1 pathways, rather than inhibition of angiogenesis, appears to be the more important mechanism for bladder cancer cell growth inhibition in UM-UC-3 and UM-UC-6 cells (Table 1B and 
